TRUDHESA Drug Patent Profile

✉ Email this page to a colleague

When do Trudhesa patents expire, and what generic alternatives are available?

Trudhesa is a drug marketed by Impel Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has sixty-four patent family members in sixteen countries.

The generic ingredient in TRUDHESA is dihydroergotamine mesylate. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dihydroergotamine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Trudhesa

A generic version of TRUDHESA was approved as dihydroergotamine mesylate by PADAGIS US on April 28^th, 2003.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for TRUDHESA?
What are the global sales for TRUDHESA?
What is Average Wholesale Price for TRUDHESA?

Summary for TRUDHESA

International Patents:	64
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	49
Patent Applications:	1,250
Drug Prices:	Drug price information for TRUDHESA
What excipients (inactive ingredients) are in TRUDHESA?	TRUDHESA excipients list
DailyMed Link:	TRUDHESA at DailyMed

Drug patent expirations by year for TRUDHESA

Pharmacology for TRUDHESA

Drug Class	Ergotamine Derivative

US Patents and Regulatory Information for TRUDHESA

TRUDHESA is protected by six US patents and one FDA Regulatory Exclusivity.

Patents protecting TRUDHESA

Nasal drug delivery device
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Nozzles for nasal drug delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Intranasal delivery of dihydroergotamine by precision olfactory device
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

In-line nasal delivery device
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Nasal drug delivery device
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Nozzles for nasal drug delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

FDA Regulatory Exclusivity protecting TRUDHESA

NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for TRUDHESA

See the table below for patents covering TRUDHESA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
European Patent Office	3341059	DISPOSITIF D'ADMINISTRATION NASALE EN LIGNE (IN-LINE NASAL DELIVERY DEVICE)	⤷ Sign Up
Israel	257845	התקן קווי למתן דרך האף (In-line nasal delivery device)	⤷ Sign Up
Russian Federation	2020125871	ИНТРАНАЗАЛЬНАЯ ДОСТАВКА ДИГИДРОЭРГОТАМИНА С ПОМОЩЬЮ ПРЕЦИЗИОННОГО УСТРОЙСТВА ДЛЯ ДОСТАВКИ В ОБОНЯТЕЛЬНУЮ ОБЛАСТЬ	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration